BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 24535095)

  • 1. FibroTest/Fibrosure for significant liver fibrosis and cirrhosis in chronic hepatitis B: a meta-analysis.
    Salkic NN; Jovanovic P; Hauser G; Brcic M
    Am J Gastroenterol; 2014 Jun; 109(6):796-809. PubMed ID: 24535095
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prospective validation of FibroTest in comparison with liver stiffness for predicting liver fibrosis in Asian subjects with chronic hepatitis B.
    Kim BK; Kim SU; Kim HS; Park JY; Ahn SH; Chon CY; Cho IR; Joh DH; Park YN; Han KH; Kim DY
    PLoS One; 2012; 7(4):e35825. PubMed ID: 22536445
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Validation of liver fibrosis biomarker (FibroTest) for assessing liver fibrosis progression: proof of concept and first application in a large population.
    Poynard T; Munteanu M; Deckmyn O; Ngo Y; Drane F; Castille JM; Housset C; Ratziu V; Imbert-Bismut F
    J Hepatol; 2012 Sep; 57(3):541-8. PubMed ID: 22612998
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Validation and comparison of indexes for fibrosis and cirrhosis prediction in chronic hepatitis C patients: proposal for a pragmatic approach classification without liver biopsies.
    Bourliere M; Penaranda G; Renou C; Botta-Fridlund D; Tran A; Portal I; Lecomte L; Castellani P; Rosenthal-Allieri MA; Gerolami R; Ouzan D; Deydier R; Degott C; Halfon P
    J Viral Hepat; 2006 Oct; 13(10):659-70. PubMed ID: 16970597
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease.
    Ratziu V; Massard J; Charlotte F; Messous D; Imbert-Bismut F; Bonyhay L; Tahiri M; Munteanu M; Thabut D; Cadranel JF; Le Bail B; de Ledinghen V; Poynard T; ;
    BMC Gastroenterol; 2006 Feb; 6():6. PubMed ID: 16503961
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Application of the HALF index obviates the need for liver biopsy in half of all patients with chronic hepatitis B.
    Lee HJ; Seo YS; Kim DJ; Kang HS; An H; Kim JH; Cheong JY; Yim HJ; Yeon JE; Lee HS; Byun KS; Cho SW; Kim DJ; Um SH; Kim CD; Ryu HS
    J Gastroenterol Hepatol; 2011 Jun; 26(6):987-95. PubMed ID: 21198828
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [A noninvasive model to predict histological liver cirrhosis in patients with chronic hepatitis B].
    Tu XL; Xiao YQ; Chen F
    Zhonghua Gan Zang Bing Za Zhi; 2009 Jan; 17(1):28-32. PubMed ID: 19203448
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of three algorithms of non-invasive markers of fibrosis in chronic hepatitis C.
    Sebastiani G; Halfon P; Castera L; Mangia A; Di Marco V; Pirisi M; Voiculescu M; Bourliere M; Alberti A
    Aliment Pharmacol Ther; 2012 Jan; 35(1):92-104. PubMed ID: 22035045
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of Fibrotest and PGAA for the diagnosis of fibrosis stage in patients with alcoholic liver disease.
    Naveau S; Essoh BM; Ghinoiu M; Marthey L; Njiké-Nakseu M; Balian A; Lachgar M; Prévot S; Perlemuter G
    Eur J Gastroenterol Hepatol; 2014 Apr; 26(4):404-11. PubMed ID: 24561990
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study.
    Imbert-Bismut F; Ratziu V; Pieroni L; Charlotte F; Benhamou Y; Poynard T;
    Lancet; 2001 Apr; 357(9262):1069-75. PubMed ID: 11297957
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discordance between liver biopsy and FibroTest in assessing liver fibrosis in chronic hepatitis B.
    Park MS; Kim BK; Cheong JY; Kim DJ; Park JY; Kim DY; Ahn SH; Han KH; Chon CY; Kim SU
    PLoS One; 2013; 8(2):e55759. PubMed ID: 23405210
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transient Elastography for Significant Liver Fibrosis and Cirrhosis in Chronic Hepatitis B: A Meta-Analysis.
    Qi X; An M; Wu T; Jiang D; Peng M; Wang W; Wang J; Zhang C; Chess Study Group OBOT
    Can J Gastroenterol Hepatol; 2018; 2018():3406789. PubMed ID: 29977884
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Usefulness of non-invasive markers for predicting liver cirrhosis in patients with chronic hepatitis B.
    Lee KG; Seo YS; An H; Um SH; Jung ES; Keum B; Yim HJ; Jeen YT; Chun HJ; Kim CD; Ryu HS
    J Gastroenterol Hepatol; 2010 Jan; 25(1):94-100. PubMed ID: 19793171
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-invasive tests in prediction of liver fibrosis in chronic hepatitis B and comparison with post-antiviral treatment results.
    Başar O; Yimaz B; Ekiz F; Giniş Z; Altinbaş A; Aktaş B; Tuna Y; Çoban S; Delibaş N; Yüksel O
    Clin Res Hepatol Gastroenterol; 2013 Apr; 37(2):152-8. PubMed ID: 23391746
    [TBL] [Abstract][Full Text] [Related]  

  • 15. APRI, the FIB-4 score, and Forn's index have noninvasive diagnostic value for liver fibrosis in patients with chronic hepatitis B.
    Ucar F; Sezer S; Ginis Z; Ozturk G; Albayrak A; Basar O; Ekiz F; Coban S; Yuksel O; Armutcu F; Akbal E
    Eur J Gastroenterol Hepatol; 2013 Sep; 25(9):1076-81. PubMed ID: 23510962
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Independent prospective multicenter validation of biochemical markers (fibrotest-actitest) for the prediction of liver fibrosis and activity in patients with chronic hepatitis C: the fibropaca study.
    Halfon P; Bourliere M; Deydier R; Botta-Fridlund D; Renou C; Tran A; Portal I; Allemand I; Bertrand JJ; Rosenthal-Allieri A; Rotily M; Sattonet C; Benderitter T; Saint Paul MC; Bonnot HP; Penaranda G; Degott C; Masseyeff MF; Ouzan D
    Am J Gastroenterol; 2006 Mar; 101(3):547-55. PubMed ID: 16542291
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of transient elastography (FibroScan), FibroTest, APRI and two algorithms combining these non-invasive tests for liver fibrosis staging in HIV/HCV coinfected patients: ANRS CO13 HEPAVIH and FIBROSTIC collaboration.
    Castera L; Winnock M; Pambrun E; Paradis V; Perez P; Loko MA; Asselineau J; Dabis F; Degos F; Salmon D
    HIV Med; 2014 Jan; 15(1):30-9. PubMed ID: 24007567
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FibroSURE as a noninvasive marker of liver fibrosis and inflammation in chronic hepatitis B.
    Zeremski M; Dimova RB; Benjamin S; Makeyeva J; Yantiss RK; Gambarin-Gelwan M; Talal AH
    BMC Gastroenterol; 2014 Jul; 14():118. PubMed ID: 24990385
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of adefovir dipivoxil on liver fibrosis and activity assessed with biochemical markers (FibroTest-ActiTest) in patients infected by hepatitis B virus.
    Poynard T; Ngo Y; Marcellin P; Hadziyannis S; Ratziu V; Benhamou Y;
    J Viral Hepat; 2009 Mar; 16(3):203-13. PubMed ID: 19175871
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fibrotest-Actitest: the biochemical marker of liver fibrosis--the Israeli experience.
    Morali G; Maor Y; Klar R; Braun M; Ben Ari Z; Bujanover Y; Zuckerman E; Boger S; Halfon P
    Isr Med Assoc J; 2007 Aug; 9(8):588-91. PubMed ID: 17877064
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.